Shortened telomeres in serous tubal intraepithelial carcinoma: An early event in ovarian high-grade serous carcinogenesis

American Journal of Surgical Pathology

Volumn 34, Issue 6, 2010, Pages 829-836

  Kuhn, Elisabetta ^a   Meeker, Alan ^a,c   Wang, Tian Li ^b,c   Sehdev, Ann Smith ^d   Kurman, Robert J ^a,b,c   Shih, Ie Ming ^a,b,c  

^a Departments of Pathology   (United States)

^b Oncology   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d Legacy Health   (United States)

Author keywords

High grade serous carcinoma; Ovarian cancer; Serous tubal intraepithelial carcinoma; Telomere

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER STAGING; CARCINOMA IN SITU; CYSTADENOCARCINOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; HUMAN; IMAGE PROCESSING; METABOLISM; OVARY TUMOR; PATHOLOGY; TELOMERE; UTERINE TUBE TUMOR;

CARCINOMA IN SITU; CYSTADENOCARCINOMA, SEROUS; FALLOPIAN TUBE NEOPLASMS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM STAGING; OVARIAN NEOPLASMS; TELOMERE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77953069152     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181dcede7     Document Type: Article

References (45)

1. Abbott DW, Thompson ME, Robinson-Benion C, et al. BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. J Biol Chem. 1999;274:18808-18812.
2. Akbay EA, Contreras CM, Perera SA, et al. Differential roles of telomere attrition in type I and II endometrial carcinogenesis. Am J Pathol. 2008;173:536-544.
3. Aubert G, Lansdorp PM. Telomeres and aging. Physiol Rev. 2008;88:557-579.
4. Cech TR. Beginning to understand the end of the chromosome. Cell. 2004;116:273-279.
5. Chen C, Hong YK, Ontiveros SD, et al. Single base discrimination of CENP-B repeats on mouse and human Chromosomes with PNA-FISH. Mamm Genome. 1999;10:13-18.
6. Cho KR, Shih IM. Ovarian cancer. Annu Rev Pathol Mech Dis. 2009;4:287-313.
7. Cosme-Blanco W, Shen MF, Lazar AJ, et al. Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep. 2007;8:497-503.
8. Counter CM, Hirte HW, Bacchetti S, et al. Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci U S A. 1994;91:2900-2904.
9. Crum CP, Drapkin R, Miron A, et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol. 2007;19:3-9. (Pubitemid 46095865)
10. Datar RH, Naritoku WY, Li P, et al. Analysis of telomerase activity in ovarian cystadenomas, low-malignant-potential tumors, and invasive carcinomas. Gynecol Oncol. 1999;74:338-345.
11. Di Cristofano A, Ellenson LH. Endometrial carcinoma. Annu Rev Pathol. 2007;2:57-85.
12. Dziaman T, Huzarski T, Gackowski D, et al. Elevated level of 8-oxo-7, 8-dihydro-20-deoxyguanosine in leukocytes of BRCA1 mutation carriers compared to healthy controls. Int J Cancer. 2009;125:2209-2213.
13. Feldser DM, Greider CW. Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell. 2007;11:461-469.
14. Folini M, Gandellini P, Zaffaroni N. Targeting the telosome: therapeutic implications. Biochim Biophys Acta. 2009;1792:309-316.
15. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
16. Hansel DE, Meeker AK, Hicks J, et al. Telomere length variation in biliary tract metaplasia, dysplasia, and carcinoma. Mod Pathol. 2006;19:772-779.
17. Hezel AF, Kimmelman AC, Stanger BZ, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006;20:1218-1249.
18. Kawai T, Hiroi S, Nakanishi K, et al. Telomere length and telomerase expression in atypical adenomatous hyperplasia and small bronchioloalveolar carcinoma of the lung. Am J Clin Pathol. 2007;127:254-262.
19. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007;31:161-169.
20. Kuo KT, Guan B, Feng Y, et al. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res. 2009;69:4036-4042.
21. Kurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34:433-443.
22. Lansdorp PM. Telomeres and disease. EMBO J. 2009;28:2532-2540.
23. Lee Y, Medeiros F, Kindelberger D, et al. Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv Anat Pathol. 2006;13:1-7.
24. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211:26-35.
25. Marquez RT, Baggerly KA, Patterson AP, et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res. 2005;11:6116-6126.
26. Meeker AK, Argani P. Telomere shortening occurs early during breast tumorigenesis: a cause of chromosome destabilization underlying malignant transformation? J Mammary Gland Biol Neoplasia. 2004;9:285-296.
27. Meeker AK, Gage WR, Hicks JL, et al. Telomere length assessment in human archival tissues: combined telomere fluorescence in situ hybridization and immunostaining. Am J Pathol. 2002;160:1259-1268.
28. Meeker AK, Hicks JL, Iacobuzio-Donahue CA, et al. Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res. 2004;10:3317-3326.
29. Muntoni A, Reddel RR. The first molecular details of ALT in human tumor cells. Hum Mol Genet. 2005; 14: R191-196.
30. Murakami J, Nagai N, Ohama K, et al. Telomerase activity in ovarian tumors. Cancer. 1997;80:1085-1092.
31. Murdoch WJ. Carcinogenic potential of ovulatory genotoxicity. Biol Reprod. 2005;73:586-590.
32. Murdoch WJ, Martinchick JF. Oxidative damage to DNA of ovarian surface epithelial cells affected by ovulation: carcinogenic implication and chemoprevention. Exp Biol Med (Maywood). 2004;229:546-552.
33. Paley PJ, Swisher EM, Garcia RL, et al. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol Oncol. 2001;80:176-180.
34. Park TW, Riethdorf S, Riethdorf L, et al. Differential telomerase activity, expression of the telomerase catalytic sub-unit and telomerase-RNA in ovarian tumors. Int J Cancer. 1999;84:426-431.
35. Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195:451-456.
36. Salani R, Kurman RJ, Giuntoli R II, et al. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Int J Gynecol Cancer. 2008;18:487-491.
37. Salvador S, Rempel A, Soslow RA, et al. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Gynecol Oncol. 2008;110:408-417.
38. Sehdev AS, Kurman RJ, Kuhn E, et al. Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase. Mod Pathol. 2010. In press.
39. Shaw PA, Rouzbahman M, Pizer ES, et al. Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. Mod Pathol. 2009;22:1133-1138.
40. Shay JW, Wright WE. Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis. 2005;26:867-874.
41. Svenson U, Roos G. Telomere length as a biological marker in malignancy. Biochim Biophys Acta. 2009;1792:317-323.
42. Tone AA, Begley H, Sharma M, et al. Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma. Clin Cancer Res. 2008;14:4067-4078.
43. Von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem Sci. 2002;27:339-344.
44. Von Zglinicki T, Saretzki G, Ladhoff J, et al. Human cell senescence as a DNA damage response. Mech Ageing Dev. 2005;126:111-117. (Pubitemid 40018484)
45. Wang SJ, Sakamoto T, Yasuda Si S, et al. The relationship between telomere length and telomerase activity in gynecologic cancers. Gynecol Oncol. 2002;84:81-84.